Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
…, M Cea, A Cagnetta, J Craigen… - Blood, The Journal …, 2014 - ashpublications.org
B-cell maturation antigen (BCMA), highly expressed on malignant plasma cells in human
multiple myeloma (MM), has not been effectively targeted with therapeutic monoclonal …
multiple myeloma (MM), has not been effectively targeted with therapeutic monoclonal …
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
…, PA Mayes, JL Craigen… - British journal of …, 2016 - Wiley Online Library
B‐cell maturation antigen ( BCMA , also termed TNFRSF 17) is an attractive therapeutic
target due to its restricted expression on normal and malignant plasma cells ( PC ). GSK …
target due to its restricted expression on normal and malignant plasma cells ( PC ). GSK …
Anti‐IL‐7 receptor α monoclonal antibody (GSK2618960) in healthy subjects–a randomized, double‐blind, placebo‐controlled study
…, A Coles, K Brown, D Su, JL Craigen… - British journal of …, 2019 - Wiley Online Library
Aim Interleukin (IL)‐7 signalling modulates T cell activity and is implicated in numerous
autoimmune diseases. The present study investigated the safety, pharmacokinetics, target …
autoimmune diseases. The present study investigated the safety, pharmacokinetics, target …
Late B cell depletion with a human anti-human CD20 IgG1κ monoclonal antibody halts the development of experimental autoimmune encephalomyelitis in marmosets
…, WK Bleeker, JD Laman, JL Craigen… - The Journal of …, 2010 - journals.aai.org
Depletion of CD20+ B cells has been related to reduced clinical activity in relapsing–remitting
multiple sclerosis. The underlying mechanism is not understood, because serum IgG …
multiple sclerosis. The underlying mechanism is not understood, because serum IgG …
Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics
R Kurrasch, JC Brown, M Chu, J Craigen… - The Journal of …, 2013 - jrheum.org
Objective. To investigate the safety and tolerability of a single subcutaneous (SC) dose of
ofatumumab, a fully human anti-CD20 monoclonal antibody, in patients with rheumatoid …
ofatumumab, a fully human anti-CD20 monoclonal antibody, in patients with rheumatoid …
B-cell depletion attenuates white and gray matter pathology in marmoset experimental autoimmune encephalomyelitis
…, JJG Geurts, JD Laman, JL Craigen… - … of Neuropathology & …, 2011 - academic.oup.com
This study investigated the effect of CD20-positive B-cell depletion on central nervous system
(CNS) white and gray matter pathology in experimental autoimmune encephalomyelitis in …
(CNS) white and gray matter pathology in experimental autoimmune encephalomyelitis in …
[HTML][HTML] Ofatumumab, a Human Mab Targeting a Membrane-Proximal Small-Loop Epitope On CD20, Induces Potent NK Cell-Mediated ADCC.
JL Craigen, WJM Mackus, P Engleberts, SR Miller… - Blood, 2009 - Elsevier
Abstract 1725 Poster Board I-751 Introduction CD20 represents a well established target for
immunotherapy of B-cell malignancies such as follicular lymphoma (FL). The standard …
immunotherapy of B-cell malignancies such as follicular lymphoma (FL). The standard …
Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum
Background: HMBD-001 is an IgG1 humanized monoclonal antibody specifically targeting
HER3, a receptor highly expressed on cancer cells in certain tumors. A bioanalytical method …
HER3, a receptor highly expressed on cancer cells in certain tumors. A bioanalytical method …
[HTML][HTML] Evaluation of BCMA as a therapeutic target in multiple myeloma using an antibody-drug conjugate
…, L McCahon, J Paterson, G Herledan, JL Craigen - Blood, 2013 - Elsevier
B-cell maturation antigen (BCMA) is upregulated at the terminal stages of plasma cell (PC)
differentiation, and is expressed on normal and malignant PC. Apart from low levels of mRNA …
differentiation, and is expressed on normal and malignant PC. Apart from low levels of mRNA …
Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign …
…, L Chamberlain, S Brett, J Tite, J Craigen - The Journal of …, 2010 - journals.aai.org
The development of a successful cancer vaccine requires the ability to break immunological
tolerance to self-Ags expressed on tumor cells. The transgenic rat insulin promoter (RIP) …
tolerance to self-Ags expressed on tumor cells. The transgenic rat insulin promoter (RIP) …